A Phase 1, Open-label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Trial Profile

A Phase 1, Open-label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 May 2017

At a glance

  • Drugs CC 90002 (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 23 May 2017 Planned number of patients changed from 78 to 71.
    • 27 Jul 2016 Planned End Date changed from 1 Sep 2019 to 1 Jul 2019.
    • 27 Jul 2016 Planned primary completion date changed from 1 Sep 2019 to 1 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top